Seahorse Bioscience provided the XF Technology for a breakthrough study at the Center for
Embryonic Cell and Gene Therapy and the Oregon National Primate Research Center, which revealed a critical first step in developing a new gene and stem cell
regenerative technique for treating patients with mitochondrial disease.

The study outlined a method for generating genetically and
functionally corrected pluripotent stem cells from patients with common mutations that have been shown to cause mitochondrial disease. Contact Seahorse for
more information on the study details.